Efficacy observation of gemcitabine and oxaliplatin combined with apatinib in treatment of patients with gallbladder cancer
10.3760/cma.j.cn115355-20191017-00469
- VernacularTitle:吉西他滨和奥沙利铂联合阿帕替尼治疗胆囊癌效果观察
- Author:
Honge YU
1
;
Guoxiang JIANG
;
Zhenhua BAO
;
Yuanliang YANG
;
Jianping YANG
Author Information
1. 山东省海阳市人民医院肿瘤科 265100
- From:
Cancer Research and Clinic
2020;32(10):693-696
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of gemcitabine and oxaliplatin combined with targeted drug apatinib in the treatment of gallbladder cancer.Methods:The data of 82 patients with gallbladder cancer who were admitted to Haiyang People's Hospital, Yantaishan Hospital and Rongjun Hospital of Yantai City in Shandong Province from May 2017 to December 2018 were retrospectively analyzed. The patients were divided into control group and observation group according to the medication, with 41 cases in each group. Patients in the control group were treated with gemcitabine combined with oxaliplatin regimen (gemcitabine 1 000 mg/m 2 was injected intravenously for 30 minutes on the 1st and 8th day, and oxaliplatin 100 mg/m 2 was injected intravenously for 3 hours on the 1st day), the observation group was combined with apatinib mesylate 500 mg/d based on the treatment method of the control group. The treatment effect, serum tumor marker levels, adverse reactions and survival were compared between the two groups. Results:The disease control rate of the control group was 70.73% (29/41), which was significantly lower than that of the observation group [92.68% (38/41)] ( χ2 = 6.609, P < 0.05). After treatment, the levels of vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA), soluble interleukin-2 receptor (sIL-2R) and Dickkopf-1 in the observation group were significantly lower than those in the observation group, and the differences were statistically significant ( t values were 6.011, 3.048, 4.444, and 4.514, all P < 0.05). The incidence of proteinuria and hand-foot syndrome in the observation group were significantly lower than those in the control group, and the differences were statistically significant ( χ2 values were 6.116 and 4.986, both P < 0.05). During the 1-year follow-up, 2 patients in the observation group died, and the survival rate was 95.13% (39/41); 8 patients in the control group died, and the survival rate was 80.49% (33/41). There was a statistical difference in the survival rate between the two groups ( χ2 = 4.100, P < 0.05). Conclusion:Gemcitabine and oxaliplatin combined with apatinib mesylate are effective in treating gallbladder cancer, which can effectively reduce serum tumor marker levels and improve the prognosis of gallbladder cancer patients.
